Cell News and Research

RSS

Scientists find potential Achilles Heel in JC polyomavirus

The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of T-bingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks.

21 Oct 2010

Researchers suggest 'watch and wait' strategy for girls with germ-cell ovarian tumors

Researchers from Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a "watch and wait" strategy to determine if the follow-up treatment is needed.

21 Oct 2010

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

21 Oct 2010

Researchers to study effect of reovirus on cancer cells

A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, are conducting a clinical trial to see if the virus can target and kill certain tumor types.

21 Oct 2010

Aastrom submits SPA for Phase 3 clinical development program in critical limb ischemia to FDA

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a special protocol assessment (SPA) describing the company's proposed Phase 3 clinical development program in critical limb ischemia (CLI).

21 Oct 2010

Study: p63 gene stifles spread of cancer

Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.

21 Oct 2010

DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy

MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

21 Oct 2010

Joint stem cell study to investigate multiple sclerosis

A $2.2 million project by Victorian and Californian researchers will assess whether stem cell therapies can be used to combat diseases such as Multiple Sclerosis and Type-1 diabetes, and help organ transplant recipients. Speaking at AusBiotech 2010 in Melbourne today, Innovation Minister Gavin Jennings said the Brumby Labor Government had contributed $575,505 to the project, the fifth to be funded through the $28 million Victoria–California Stem Cell Alliance which was established in 2008 under the Biotechnology Strategic Development Plan.

21 Oct 2010

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

Overweight dads may pass on diabetes to their daughters: Study

According to a latest study fathers on a high-fat diet are more likely to produce daughters with a higher diabetes risk. The study was published in the journal Nature and it involved laboratory rats.

20 Oct 2010

Envoy expands drug discovery collaboration with The Scripps Research Institute

Envoy Therapeutics, Inc., a recently-formed drug discovery company, today announced that it has expanded its research collaboration with The Scripps Research Institute aimed at identifying new drugs for neurological and psychiatric diseases.

20 Oct 2010

Rockwell Medical announces design of Phase III development program for Soluble Ferric Pyrophosphate

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic.

20 Oct 2010

Elsevier / MC Strategies partners with AORN to develop latest module for Perioperative Collection

Elsevier / MC Strategies a pioneer in providing e-learning solutions to more than 1,300 healthcare organizations, has partnered with the Association of periOperative Registered Nurses (AORN) to develop the latest module for Mosby's Nursing Skills Perioperative Collection, the only perioperative-specific set of nursing skills approved by AORN to be consistent with the Standards and Recommended Practices.

20 Oct 2010

RWV bioreactor creates 3-D cell culture models

The cells and tissues in our bodies grow, develop and interact in a highly complex, three-dimensional world. Likewise, the various microbial pathogens that invade our bodies and cause infectious disease interact with this complex 3-D tissue milieu. In the current issue of the journal Nature Reviews Microbiology, researcher Cheryl Nickerson and her team at the Biodesign Institute at Arizona State University highlight an innovative approach for studying cells in 3-D.

20 Oct 2010

JIPH selected for inclusion in MEDLINE Indexing

Elsevier Middle East announces that the Journal of Infection and Public Health (JIPH) has been selected for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM). Citations for articles indexed, the indexing terms and the abstract printed in the journal are now searchable using PubMed (http://www.pubmed.gov). Indexing using the US National Library of Medicine's (NLM) advanced MeSH terminology will be retroactive from Volume 1, Issue 1 (2008) of the journal.

20 Oct 2010

Highlights of world's largest ophthalmic education conference

Results of clinical research on new presbyopia treatments now available in Europe-and possibly available soon in the United States-were reported in today's Scientific Program of the 2010 Joint Meeting of the American Academy of Ophthalmology (AAO) and Middle East-Africa Council of Ophthalmology (MEACO). The AAO-MEACO meeting is the world's largest, most comprehensive ophthalmic education conference and is in session October 16 through 19 at McCormick Place, Chicago.

20 Oct 2010

PBS-Bio announces three new contracts to develop cancer therapy

In an industry that faces increasing challenges in delivering new drugs to patients, Predictive Biomarker Sciences (PBS-Bio) today announced three new contracts aimed at bringing new medicines to the marketplace.

20 Oct 2010

China Cord Blood files amendment to Annual Report on Form 20-F/A

China Cord Blood Corporation the first and largest cord blood bank operator in China, today announced that the Company has filed an amendment to its Annual Report on Form 20-F/A, which included audited financial statements for the fiscal year ended March 31, 2010 with the U.S. Securities and Exchange Commission.

20 Oct 2010